GSE142631 Transcriptomic programming of human CD8+ T cells. By pDCs and cDC2s jin the context of DC-based cancer vaccines

Contributor : Johannes TextorSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCancer vaccines utilizing naturally circulating dendritic cell (DC) subsets, such as plasmacutoid DCs (pDCs) and type 2 convential DCs (cDC2s), have demonstrated their potential as a therapy. For melanoma in recent clinical trials. These DC vaccines aim to. human. DC subsets on the. T cell transcriptional program, which. forms the. molecular. basis. of an. antitumor. T cell response, is. poorly understood. In. this study, we investigated the eraly gene expressionsignature of CD8+ T. cells following. stimulation by pDCs or cDC2s. in. a culture system that mimics. the. current protocol of primary DC-based cancer vaccines. Our results demonstrate that pDCs and cDC2s induce a remarkably similar transcriptomic profile in CD8_ T cells, which. is tailored for increased effector function, survival and sensitivity. towards secondary signals. Nonetheless, differences between pDC- and cDC2-induced T cell gene expression signatures encompass genes with a role in proliferation, cytolytic capacity and differentiation. Combining both DC subsets results in a T cell. transcriptomic program that. is very. similar to. the program induced by. pDCs alone. The results suggest that the. choice of DC subsets for use in cancer vaccines impacts the induced antitumor CD8+ T cell response.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Authors: Boos L, Leslie I, Larkin J Abstract Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance are needed.Areas covered: Current treatment strategies and landmark trials are discussed.Novel targeted agents, immune checkpoint inhibitors and further immune-modulatory drugs, cancer vaccines and tumour infiltrating lymphocytes and their potential role in t...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Could BCG, a 100-year-old Vaccine for Tuberculosis, Protect Against Coronavirus? appeared first on Inter Press Service.
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Source Type: news
In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX ™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid p hosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of an...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
AbstractImmunotherapies are often used for the treatment, remission, and possible cure of autoimmune diseases, infectious diseases, and cancers. Empirical evidence illustrates that females and males differ in outcomes following the use of biologics for the treatment of autoimmune diseases, e.g., rheumatoid arthritis (RA), infectious diseases, e.g., influenza, and solid tumor cancers. Females tend to experience more adverse reactions than males following the use of a class of biologics referred to as immunotherapies. For immunotherapies aimed at stimulating an immune response, e.g., influenza vaccines, females develop great...
Source: Biology of Sex Differences - Category: Biology Source Type: research
schow Survival of gastrointestinal cancer remains dismal, especially for metastasized disease. For various cancers, especially melanoma and lung cancer, immunotherapy has been proven to confer survival benefits, but results for gastrointestinal cancer have been disappointing. Hence, there is substantial interest in exploring the usefulness of adaptive immune system education with respect to anti-cancer responses though vaccination. Encouragingly, even fairly non-specific approaches to vaccination and immune system stimulation, involving for instance influenza vaccines, have shown promising results, eliciting hopes that...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mil...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Volume 9, Issue 1, January 2020 .
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsCurrent clinical trials are exploring combination therapy and novel treatment strategies beyond immune checkpoint therapies and vaccine therapy such as CAR T cells. There is also an effort to establish synergy between immunotherapy and current standard of care. Furthermore, recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific GBM treatment.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
This study showed that carefully selected patients with locally advanced and metastatic forms of malignant melanoma and renal cell carcinoma could potentially have long-term disease control with a tag-7 gene-modified tumor cells-based vaccine. Randomized clinical trials in patients whose tumors produce low amounts of immunosuppressive factors are needed to confirm this hypothesis in both the adjuvant and metastatic settings. Graphic expression of the quantitative content of immunosuppressive factors in the supernatants of cultures of tumor cells of patients with sufficient and insufficient clinical effect. ABBREVIATIO...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
CONCLUSION: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment. PMID: 32224538 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Genetics | Melanoma | Skin Cancer | Study | Vaccines